Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

Just Released: "Rituxan (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022"


Print article Print article
2013-12-11 10:25:34 - New Pharmaceuticals market report from GlobalData: "Rituxan (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022"

Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While SLE can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN). The term LN refers to SLE patients with glomerulonephritis, and when the term LN is used, glomerular tissue injury in the kidneys is always involved. Renal injury without any glomerular involvement is classified as nephritis in a patient with SLE.

Full Report Details at
- www.fastmr.com/prod/752922_rituxan_systemic_lupus_erythematosus_ ..

Rituxan is a monoclonal antibody that binds to the transmembrane antigen CD20 expressed on B-cells. Its binding to B-cells mediates their apoptotic death and depletion. Rituxan

was initially developed for the treatment of non-Hodgkin's lymphoma and subsequently gained marketing approvals for use in RA, chronic lymphocytic leukemia (CLL) and granulomatosis (Roche, 2013).

Scope

* Overview of SLE-LN, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Rituxan including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Rituxan for the top seven countries from 2012 to 2022.
* Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for SLE-LN
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Rituxan performance
* Obtain sales forecast for Rituxan from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Report Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Prognosis
3.3 Quality of Life
3.4 Symptoms
4 Disease Management
4.1 Diagnosis Overview
4.1.1 SLE Diagnosis
4.1.2 LN Diagnosis
4.2 Treatment Overview
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Rituxan (rituximab)
6.1 Overview
6.2 Efficacy
6.3 Safety
6.4 SWOT Analysis
6.5 Forecast
7 Appendix
7.1 Bibliography
7.2 Abbreviations
7.3 Methodology
7.4 Forecasting Methodology
7.4.1 Diagnosed SLE and LN Patients
7.4.2 Percent Drug-Treated Patients
7.4.3 General Pricing Assumptions
7.4.4 Drug Assumption
7.4.5 Generic Erosion
7.5 Physicians and Specialists Included in this Study
7.6 Primary Research - Prescriber Survey
7.7 About the Authors
7.7.1 Analysts
7.7.2 Global Head of Healthcare
7.8 About GlobalData
7.9 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Symptoms of SLE
Table 2: 1997 Updated ACR Criteria for Classification of SLE
Table 3: The SLICC Clinical and Immunologic Criteria for Classification of SLE
Table 4: WHO and ISN/RPS classifications of LN
Table 5: Treatment Guidelines for SLE and LN
Table 6: Most Prescribed Drugs for SLE and LN by Class in the Global Markets, 2013
Table 7: Leading Treatments for SLE and LN, 2013
Table 8: Product Profile - Rituxan
Table 9: Rituxan SWOT Analysis, 2013
Table 10: Global SLE Sales Forecasts ($m) for Rituxan, 2012-2022
Table 11: Global LN Sales Forecasts ($m) for Rituxan, 2012-2022
Table 12: Number of Physicians Surveyed by Country

List of Figures

1.2 List of Figures
Figure 1: Overview of the Etiology and Pathogenesis of SLE
Figure 2: Overview of the BAFF/APRIL Ligand and Receptor System
Figure 3: Overview of the Treatment Management of SLE

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser